A Phase 1-2 Study of Lutetium-FAP for People With Advanced Pancreatic Cancer

Full Title

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor

Purpose

Researchers are assessing Lutetium-FAP for people with advanced pancreatic cancer. Lutetium-FAP is a drug with a radioactive part attached. It targets cancer cells that make a protein called FAP, which may help cancer grow and survive. Lutetium-FAP combines a radiation-emitting metal with a tumor-targeting agent to deliver radiation into a tumor and destroy cancer cells.

If you take part in this study, you will get one of these treatments:

• Lutetium-FAP alone (for people who have had up to 2 prior regimens of cancer therapy)
• Lutetium-FAP with mFOLFIRINOX (for people who have had no prior cancer treatment)

mFOLFIRINOX is a combination of standard chemotherapy drugs used to treat people with pancreatic cancer.  

Who Can Join

To join this study, there are a few conditions. You must:

• Have pancreatic cancer that has spread beyond its original location.
• Have received either no treatment for the cancer or up to 2 regimens of therapy.
• Have completed previous anti-cancer treatment at least 2 weeks before getting the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Fiyinfolu Balogun’s office at 646-888-6964.